Stonebraker Jaclyn R, Ooi Chee Y, Pace Rhonda G, Corvol Harriet, Knowles Michael R, Durie Peter R, Ling Simon C
Marsico Lung Institute/Cystic Fibrosis Research Center, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Discipline of Pediatrics, School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, Australia; Department of Gastroenterology, Sydney Children's Hospital Randwick, Sydney, Australia.
Clin Gastroenterol Hepatol. 2016 Aug;14(8):1207-1215.e3. doi: 10.1016/j.cgh.2016.03.041. Epub 2016 Apr 5.
BACKGROUND & AIMS: Liver disease is the third leading cause of death in patients with cystic fibrosis (CF), but features of patients with CF, severe liver disease, and portal hypertension have not been characterized fully.
We performed a retrospective analysis of data from 561 patients with CF (63% male, 99% with pancreatic insufficiency), liver disease (hepatic parenchymal abnormalities consistent with cirrhosis, confirmed by imaging), and portal hypertension (esophageal varices, portosystemic collaterals, or splenomegaly), with no alternate causes of liver disease. All patients were enrolled in the Genetic Modifier Study of Severe CF Liver Disease at 76 international centers, from January 1999 through July 2013.
Male patients were diagnosed with liver disease at a younger age than female patients (10 vs 11 y; P = .01). Splenomegaly was observed in 99% of patients and varices in 71%. Levels of liver enzymes were near normal in most patients. Thrombocytopenia affected 70% of patients and was more severe in patients with varices (88 × 10(9)/L vs 145 × 10(9)/L; P < .0001). Ninety-one patients received liver transplants (16%), at a median age of 13.9 years. Compared with patients who did not receive liver transplants, patients who received liver transplants had lower platelet counts (78 × 10(9)/L vs 113 × 10(9)/L; P < .0001), higher international normalized ratios (P < .0001), and lower levels of albumin (P = .0002). The aminotransferase to platelet ratio index (APRi) and fibrosis index based on 4 factor (FIB-4) values were higher than the diagnostic thresholds for CF liver disease in 96% and in 90% of patients, respectively. Patients who received liver transplants or who had varices had higher APRi and FIB-4 values than patients who did not.
In patients with CF, severe liver disease develops early in childhood (approximately 10 years of age), and is more common in boys than in girls. Patients with varices and those who receive liver transplants have more abnormal platelet counts and APRi and FIB-4 scores.
肝脏疾病是囊性纤维化(CF)患者的第三大死因,但CF患者、严重肝脏疾病患者以及门静脉高压患者的特征尚未得到充分描述。
我们对561例CF患者(63%为男性,99%有胰腺功能不全)的数据进行了回顾性分析,这些患者患有肝脏疾病(影像学证实肝脏实质异常符合肝硬化)和门静脉高压(食管静脉曲张、门体分流或脾肿大),且无其他肝脏疾病病因。所有患者均于1999年1月至2013年7月期间在76个国际中心参加了严重CF肝病基因修饰研究。
男性患者比女性患者更早被诊断出患有肝脏疾病(10岁对11岁;P = 0.01)。99%的患者观察到脾肿大,71%的患者有静脉曲张。大多数患者的肝酶水平接近正常。血小板减少症影响了70%的患者,且在有静脉曲张的患者中更为严重(88×10⁹/L对145×10⁹/L;P < 0.0001)。91例患者接受了肝移植(16%),中位年龄为13.9岁。与未接受肝移植的患者相比,接受肝移植的患者血小板计数更低(78×10⁹/L对113×10⁹/L;P < 0.0001),国际标准化比值更高(P < 0.0001),白蛋白水平更低(P = 0.0002)。氨基转移酶与血小板比值指数(APRi)和基于4项指标的纤维化指数(FIB-4)值分别在96%和90%的患者中高于CF肝病的诊断阈值。接受肝移植或有静脉曲张的患者APRi和FIB-4值高于未接受肝移植的患者。
在CF患者中,严重肝脏疾病在儿童早期(约10岁)就会发生,且在男孩中比女孩中更常见。有静脉曲张的患者和接受肝移植的患者血小板计数、APRi和FIB-4评分更异常。